J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion
Deals·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Johnson & Johnson announced collaboration with privately held Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases, J&J said in a statement.
The deal gives J&J the option to acquire Sail Biomedicines for $2.6 billion.
Johnson & JohnsonSail Biomedicines
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Johnson & Johnson announced collaboration with privately held Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases, J&J said in a statement.”
Bloomberg — J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion